Abstract
The use of bromocriptine for the suppression of postpartum lactation drew widespread attention to a potentially increased risk for cardiovascular and cerebrovascular adverse effects. To estimate the incidence of these events a follow-up study was performed among 2,130 women of 15–44 years of age who were treated with a course of bromocriptine in 1990–1992. None of these women were admitted to the hospital for cardiovascular or cerebrovascular events. However, the incidence of pregnancy hypertension and the use of cardiovascular drugs increased considerably in the last 2 months before delivery. Therefore, cardiovascular or cerebrovascular events can probably be explained by pre-existing morbidity rather than by the use of bromocriptine. We estimated, using a ‘worst-case’ analysis, that fewer than 2 Dutch women each year would develop serious cardiovascular or cerebrovascular events.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Postpartum hypertension, seizures, strokes reported with bromocriptine. FDA Drug Bull 1984;14(1):3–4.
Katz M, Kroll D, Pak I, Osimoni A, Hirsch M. Puerpual hypertension, stroke, and seizures after suppression of lactation with bromocriptine. Obstet Gynecol 1985;66(6):822–4.
Iffy L, Ten Hove W, Frisoli G. Acute myocardial infarction in the puerperium in patients receiving bromocriptine. Am J Obstet Gynecol 1986;155(2):371–2.
Ruch A, Duhring JL. Postpartum myocardial infarction in a patient receiving bromocriptine. Obstet Gynecol 1989:74(3 pt 2):448–51.
Gittelman DK. Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage. Gen Hosp Psychiatry 1991;13(4):278–80.
Eickman FM. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol 1992;15(10):781–3.
Larrazet F, Spaulding C, Lobreau HJ, Weber S, Guerin F. Possible bromocriptine-induced myocardial infarction. Ann Intern Med 1993;118(3):199–200.
FDA to act on Sandoz Parlodel®. Scrip 1993;1855:10.
Woodcock J. Bromocriptine mesylate: withdrawal of approval of the indication for the prevention of physiological lactation. Fed Reg 1995;60(19):3404–5.
Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands [dissertation]. Utrecht: Utrecht University, 1993.
Anatomical Therapeutic Chemical (ATC) classification index: Including defined daily doses (DDD) for plain substances. Oslo: World Health Organization, 1992.
WHO. International Classification of Diseases. 9th Clinical Modification (ICD-9-CM). Geneva: World Health Organization, 1987.
Vademecum of health statistics of the Netherlands 1993. ′s-Gravenhage: Netherlands Central Bureau of Statistics & Ministry of Welfare, Health and Cultural Affairs, 1993.
Fournié A, Graille V, Montastruc JL. Bromocriptine, lactation inhibition and pharmacovigilance. J Gynecol Obstet Biol Reprod 1994;23:129–30.
Watson DL, Bhatia RK, Norman GS, Brindley BA, Sokol RJ. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension. Obstet Gynecol 1989;74(4):573–6.
Vandenbroucke JP, Hofman A. Grondslagen der epidemiologie [Fundamentals of epidemiology]. Utrecht: Bunge, 1993.
Healey M. Suppressing lactation with oral diuretics [letter]. Lancet 1961:1353–4.
De Jong-van den Berg LTW. Drug utilization studies in pregnancy: what can they contribute to safety assessment? [dissertation]. Groningen: University of Groningen, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herings, R.M.C., Stricker, B.H.C. Bromocriptine and suppression of postpartum lactation. Pharm World Sci 17, 133–137 (1995). https://doi.org/10.1007/BF01872390
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01872390